Page 7 - Arcus Bioscience News Today

09.12.2022 - Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the Compensation Committee of the Company’s Board of Directors granted five new employees ...

Overdone Selloff? Fed Talking Heads, Trading Gilead, Iger's Magic Disney Words: Market Recon...SJR

24.11.2022 - Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the Compensation Committee of the Company’s Board of Directors granted seven new employees ...

Dr. Nuyten will oversee Arcus’s clinical development organization that includes nearly 200 employees and six clinical-stage programs targeting TIGIT, the adenosine axis (CD73 and dual A2a/A2b), HIF-2a and PD-1HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceu...

In a third interim analysis for the randomized Phase 2 ARC-7 study, both anti-TIGIT domvanalimab-containing arms continued to show meaningful differentiation compared to the anti-PD1 antibody zimberelimab alone when given as a treatment for first-line metastatic non-small cell lung cancer (NSCLC); we expect to provi...

Equities analysts expect Arcus Biosciences, Inc. (NYSE:RCUS – Get Rating) to announce $163.47 million in sales for the current quarter, Zacks reports. Three analysts have made estimates for Arcus Biosciences’ earnings, with the highest sales estimate coming in at $444.90 million and the lowest estimate coming in at $22.50 million. Arcus Biosciences reported sales of […]

Arcus Biosciences (NYSE:RCUS – Get Rating)‘s stock had its “overweight” rating reissued by investment analysts at Cantor Fitzgerald in a report issued on Friday, Zacks.com reports. Cantor Fitzgerald also issued estimates for Arcus Biosciences’ FY2022 earnings at ($3.32) EPS and FY2022 earnings at ($4.22) EPS. RCUS has been the subject of a number of other […]

The current chemotherapy-dominated landscape of cervical cancer treatment is set to change to include multiple different drug classes. ...

Feb 2, 2021 10:50am Coherus BioSciences is shelling out $150 million upfront for U.S. and Canadian rights to Junshi Biosciences’ PD-1 inhibitor toripalimab. (Kritchanut/iStock/Getty Images Plus/Getty Images) On the heels of Novartis licensing BeiGene’s tislelizumab, another China-made PD-1 inhibitor has found itself a new U.S. collaborator in a company that’s just pivoting to immuno-oncology. Coherus BioSciences is shelling out $150 million upfront for U.S. and Canadian rights to Junshi B...